Consensus NeuroSense Therapeutics Ltd.

Equities

NRSN

IL0011809592

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-13 pm EDT			5-day change	1st Jan Change
1.15 ^USD	-2.54%		-9.45%	+46.50%

May. 07	NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients	CI
Apr. 22	NeuroSense to Collaborate With Genetika+ on Alzheimer's Disease Drug Development; Shares Fall	MT

Evolution of the average Target Price on NeuroSense Therapeutics Ltd.

Price target over the last 5 years

History of analyst recommendation changes

27d380c9155078f.Ls4Gmk9c9z12AGr2WikO-4UErGgtN2mec_LdmW3uFpM.So9ergE5vVMyYiDFG2xvnMtG-Q94BA3ZFZaZ3D6Ie9hjv0_FOWinDDcwAQ~f8805286d4673cf67950ee9d18215a04

Analyst Recommendations on NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Prices $4.5 Million Offering of Ordinary Shares, Warrants	Apr. 11	MT
Alliance Global Partners Initiates NeuroSense Therapeutics at Buy Rating With $7.50 Price Target	23-07-17	MT
Maxim Starts NeuroSense Therapeutics at Buy with $7 Price Target	22-01-07	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.15 USD

Average target price

5.25 USD

Spread / Average Target

+356.52%

High Price Target

7.5 USD

Spread / Highest target

+552.17%

Low Price Target

3 USD

Spread / Lowest Target

+160.87%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NeuroSense Therapeutics Ltd.

Alliance Global Partners
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar